Detalhe da pesquisa
1.
Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study.
Int J Rheum Dis;
27(3): e15091, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38433479
2.
Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study.
J Clin Med;
11(14)2022 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35887946